Suppr超能文献

与肝细胞癌预后不良相关的CFHR4的鉴定。

Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma.

作者信息

Ding Qinglin, Li Hanluo, Xu Zhigao, Hu Kanghong, Ye Qifa

机构信息

Sino-German Biomedical Center, National Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology, Wuhan, China.

Institute of Hepatobiliary Diseases of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Zhongnan Hospital of Wuhan University, Wuhan, China.

出版信息

Front Oncol. 2022 Oct 20;12:812663. doi: 10.3389/fonc.2022.812663. eCollection 2022.

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is one of the most leading causes of cancer death worldwide. The 5-year survival rate of HCC patients remains low due to the lack of early-stage symptoms. Human complement factor H-related protein 4 (CFHR4) is a critical gene that belongs to the factor H family of plasma glycoproteins, which has not been linked to HCC development. The correlations between CFHR4 and prognosis and tumor-infiltrating lymphocytes in HCC are yet unknown. The present study demonstrated the involvement of CFHR4 in HCC data mining approaches.

RESULTS

A total of 18 upregulated and 67 down-regulated differentially expressed genes (DEGs) were identified. Importantly, CFHR4, which was screened from DEGs, was shown to express at a lower level in HCC tumor tissue than normal tissues. Western blotting (WB), immunohistochemical (IHC) and quantitative reverse transcription PCR (qRT-PCR) experiments of clinical samples further validated CFHR4 was aberrantly expressed in HCC patients; Data from TCGA showed that CFHR4 was inversely correlated with a cancer family history, histological grade, tumor node metastasis (TNM) stage, and serum AFP level of HCC patients; Univariate and multivariate analyses revealed that low expression of CFHR4 was an independent predictive marker in patients with HCC; Kaplan-Meier analysis showed that the lower expression of CFHR4 was significantly associated with the progression of HCC and poor prognosis rates. Furthermore, TIMER analysis indicated that CFHR4 expression levels had correlations with infiltrating levels of immune cells in HCC.

CONCLUSION

CFHR4 expression was low in HCC and was significantly related to the poor prognosis of HCC and the level of immune infiltration. CFHR4 played important roles in regulating the initiation and progression of HCC and could be a potential biomarker for the diagnosis and prognosis of HCC.

METHODS

The expression of CFHR4 was analyzed by GEO and TCGA-LIHC database and verified by WB and IHC assay. The biological function of CFHR4 was performed by GO and KEGG enrichment analysis, and the genomic alteration of CFHR4 was investigated by cBioPortal database.The correlation between CFHR4 expression and clinical relevance was evaluated through Cox proportional hazards model, and the correlation between CFHR4 expression and tumor immune infiltrates were studied by TIMER database.

摘要

背景

肝细胞癌(HCC)是全球癌症死亡的主要原因之一。由于缺乏早期症状,HCC患者的5年生存率仍然很低。人补体因子H相关蛋白4(CFHR4)是一种关键基因,属于血浆糖蛋白的因子H家族,尚未发现其与HCC的发生有关。CFHR4与HCC预后及肿瘤浸润淋巴细胞之间的相关性尚不清楚。本研究通过数据挖掘方法证明了CFHR4参与了HCC的发生发展。

结果

共鉴定出18个上调和67个下调的差异表达基因(DEG)。重要的是,从DEG中筛选出的CFHR4在HCC肿瘤组织中的表达水平低于正常组织。临床样本的蛋白质免疫印迹(WB)、免疫组织化学(IHC)和定量逆转录聚合酶链反应(qRT-PCR)实验进一步验证了CFHR4在HCC患者中异常表达;来自癌症基因组图谱(TCGA)的数据显示,CFHR4与HCC患者的癌症家族史、组织学分级、肿瘤淋巴结转移(TNM)分期和血清甲胎蛋白(AFP)水平呈负相关;单因素和多因素分析显示,CFHR4低表达是HCC患者的独立预测标志物;Kaplan-Meier分析表明,CFHR4低表达与HCC进展和不良预后率显著相关。此外,TIMER分析表明,CFHR4表达水平与HCC中免疫细胞浸润水平相关。

结论

CFHR4在HCC中表达较低,与HCC的不良预后和免疫浸润水平显著相关。CFHR4在调节HCC的发生和发展中起重要作用,可能是HCC诊断和预后的潜在生物标志物。

方法

通过基因表达综合数据库(GEO)和TCGA肝癌(TCGA-LIHC)数据库分析CFHR4的表达,并通过WB和IHC检测进行验证。通过基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析来研究CFHR4的生物学功能,并通过cBioPortal数据库研究CFHR4的基因组改变。通过Cox比例风险模型评估CFHR4表达与临床相关性之间的关系,并通过TIMER数据库研究CFHR4表达与肿瘤免疫浸润之间的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbd2/9632743/3313dbcb535e/fonc-12-812663-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验